PAMELA JAMES: Open Payments
NPI 1285189217 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$830 in 33 payments from 23 companies in 2025. Trend: 2023 $2,369 · 2024 $1,941 · 2025 $830
Food & beverage: $730Education: $100
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $125 |
| Novartis Pharmaceuticals Corporation | 4 | $95 |
| AstraZeneca Pharmaceuticals LP | 3 | $73 |
| ARRAY BIOPHARMA INC | 2 | $57 |
| Celgene Corporation | 2 | $52 |
| Janssen Biotech, Inc. | 2 | $46 |
| PFIZER INC. | 2 | $39 |
| Genentech USA, Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Merck Sharp & Dohme LLC | 1 | $25 |
Products named: ENHERTU, KISQALI, BRAFTOVI, IMFINZI, REBLOZYL, Xtandi, Alecensa, PROVENGE.
Industry payments across AL — which companies pay providers there.
